

C1 vs Pathway Expression

	C1		IC(Δ)	P-val	FDR
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP			0.935(0.003)	2.62e-06	1.82e-05
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN			0.913(0.004)	2.62e-06	1.82e-05
COLDREN_GEFITINIB_RESISTANCE_DN			0.905(0.006)	2.62e-06	1.82e-05
LANDIS_BREAST_CANCER_PROGRESSION			0.903(0.004)	2.62e-06	1.82e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL			0.902(0.005)	2.62e-06	1.82e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL			0.902(0.004)	2.62e-06	1.82e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP			0.894(0.006)	2.62e-06	1.82e-05
LIM_MAMMARY_STEM_CELL_DN			0.881(0.005)	2.62e-06	1.82e-05
BOYALT_LIVER_CANCER_SUBCLASS_G1_UP			0.881(0.005)	2.62e-06	1.82e-05
AIGNER_ZEB1_TARGETS			0.879(0.006)	2.62e-06	1.82e-05
LANDIS_ERBB2_BREAST_TUMORS_324			0.878(0.007)	2.62e-06	1.82e-05
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP			0.878(0.005)	2.62e-06	1.82e-05
WALLACE_PROSTATE_CANCER_UP			0.873(0.005)	2.62e-06	1.82e-05
WAMUNYOKOLI_OVARIAN_CANCER_LMP			0.872(0.005)	2.62e-06	1.82e-05
LANDIS_BREAST_CANCER_PROGRESSION_UP			0.872(0.007)	2.62e-06	1.82e-05
GROGER_EMT_DN			0.869(0.007)	2.62e-06	1.82e-05
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP			0.867(0.006)	2.62e-06	1.82e-05
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN			0.864(0.006)	2.62e-06	1.82e-05
LIM_MAMMARY_LUMINAL_MATURE_UP			0.856(0.007)	2.62e-06	1.82e-05
TAUBE_EMT_DN			0.856(0.008)	2.62e-06	1.82e-05
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY			-0.811(0.009)	2.62e-06	1.18e-05
BOQUEST_STEM_CELL			-0.814(0.008)	2.62e-06	1.18e-05
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION			-0.818(0.008)	2.62e-06	1.18e-05
JAEGER_METASTASIS			-0.821(0.008)	2.62e-06	1.18e-05
SENGUPTA_NASOPHARYNGEAL_CARCINOMA			-0.828(0.006)	2.62e-06	1.18e-05
NGO_MALIGNANT_GLIOMA_1P_LOH			-0.831(0.015)	2.62e-06	1.18e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN			-0.834(0.008)	2.62e-06	1.18e-05
MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_UP			-0.841(0.011)	2.62e-06	1.18e-05
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL			-0.844(0.007)	2.62e-06	1.18e-05
COLDREN_GEFITINIB_RESISTANCE_UP			-0.851(0.007)	2.62e-06	1.18e-05
SMID_BREAST_CANCER_NORMAL_LIKE			-0.863(0.007)	2.62e-06	1.18e-05
ONDER_CDH1_TARGETS_2			-0.869(0.006)	2.62e-06	1.18e-05
ROY_WOUND_BLOOD_VESSEL			-0.873(0.006)	2.62e-06	1.18e-05
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE			-0.873(0.005)	2.62e-06	1.18e-05
LIM_MAMMARY_STEM_CELL			-0.877(0.004)	2.62e-06	1.18e-05
GU_PDEF_TARGETS			-0.880(0.005)	2.62e-06	1.18e-05
TAUBE_EMT			-0.881(0.005)	2.62e-06	1.18e-05
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL			-0.885(0.005)	2.62e-06	1.18e-05
GROGER_EMT			-0.892(0.005)	2.62e-06	1.18e-05
COLDREN_GEFITINIB_RESISTANCE			-0.904(0.006)	2.62e-06	1.18e-05